Navigation Links
Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool
Date:4/29/2008

http://www.cardinalhealth.com .


'/>"/>
SOURCE Cardinal Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
6. Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs. Angiographic Guidance of Stent Deployment in Patients with Multivessel Disease
7. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
11. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 1AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 2Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 1Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 2Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 3Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 4Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 5Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 6Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 7Child Food Allergies on the Rise in U S 61410 1Child Food Allergies on the Rise in U S 61410 2Child Food Allergies on the Rise in U S 61410 3
...nificant Reduction in Relapse Rate , , - Secondar... of Patients Relapse-Free and Disability Progressi...e Tablets Planned for mid-2009 , , SEATTLE and GE...KGaA, announced today detailed results of the two-... III trial using Cladribine Tablets (Merck Serono,...
...y and safety for extended release and immediate re...ril 29 /PRNewswire/ -- New findings from two dou...ty and tolerability of pramipexole dihydrochloride...ation, for the treatment of Parkinson,s disease (P...emy of Neurology (AAN) 61st Annual Meeting in Seat...
Other Medicine Technology:Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 2Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 3Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 4Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 5Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 6Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 7New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 2New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 3New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 4New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 5
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...ica who had treated injured protestors while takin...red to // leave Nepal by the King Gyanendra's gove...reportedly detained Wednesday after he appeared on...ipur television channel that truncheon-wielding po...
...gograd, in Russia, has reported the deadly H5N1 st...rom the state veterinary authorities.// This is t...ns in Southern Russia have reported Bird-Flu infec...t died in Volgograd, have tested positive for the ...
... India, which is in its infancy demands a lot of f... Indian Council of Medical Research (ICMR).// ...allenges in stem cell research in India', Ganguly ...nding and a regulatory framework for ethical pract...
...o reverse the process of cell division. This proce...inding could be an important milestone in the figh...llably. Researchers from the Oklahoma Medical ...r, there has to be a perfect co-ordination between...
... suicide rate in England is at its lowest ever wit...population from 2002 to 2004. It is also noted tha...steady fall in the number of young men committing ...ointly issued by the Department of Health and the ...
...perts about the hearing loss caused by the MP3 pla...hout paying// any heed to those warnings. But sens...s have now started limiting the volume on the devi...s. The ASHA said having the volume up too loud and...
Other Medicine News:Health News:Sensing The Health Hazard MP3 Makers Tone Down The Volume 2
Full Body Girdle V-1655
Body Suit w/Bra above knee, Front Closure
Compression Vest V-640
Male Compression Vest Binder
Medicine Products: